
Opinion|Videos|July 16, 2026
Differentiating Revumenib and Ziftomenib: Label vs Perception
Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.
Episodes in this series

In this episode, Zepcan compares the actual label data side by side, addressing agent complexity and monitoring requirements. She examines QTc monitoring, CYP3A4 interactions, PPI interactions, and pharmacokinetic profiles to help guide pharmacy practice.
Latest CME
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
3
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5






































































































